UNSPSC 51314311: Brompheniramine/guaifenesin/menthol/phenylephrine/phenylpropanolamine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.

UNSPSC 51314311 Brompheniramine/guaifenesin/menthol/phenylephrine/phenylpropanolamine is a Commodity code covering branded and generic combination cold and allergy medications used in state and local public health and emergency response programs. Recent solicitations show state and local governments procuring these products as part of broader pharmacy benefit programs, emergency medical supply stockpiles, and over-the-counter product distribution through authorized wholesaler networks. The issuing bodies include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances serving both state and local jurisdictions. Scope of work ranges from direct procurement of naloxone and emergency drug-related supplies (which may include OTC respiratory products) to participation in statewide generic pharmaceutical contracts that bundle this commodity with hundreds of other medications and OTC items for distribution across participating public facilities.

Recent activity appears concentrated in Florida and Minnesota, with exploratory procurement underway in Texas. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP posted January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products; proposals require detailed product specifications including NDC codes, pricing through authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson), and cGMP and Drug Supply Chain Security Act compliance, with contract effective July 1, 2026. Seminole County, Florida posted an IFB (IFB60459723LAS) on June 30, 2026 (due July 26, 2023) for annual procurement of naloxone and drug deactivation systems with quarterly deliveries and a two-year initial term plus optional one-year renewal. The Texas Health and Human Services Commission issued an RFI (HHS0017013) on April 3, 2026 to gather market intelligence on direct-to-manufacturer prescription programs, signaling potential future formal procurement activity in that state.